Expanding Horizons: scPharmaceuticals’ Furoscix Gains FDA Approval for CKD, Broadening Market Potential

Leerink Partners analyst Roanna Ruiz has maintained their bullish stance on SCPH stock, giving a Buy rating on March 7.

Roanna Ruiz’s rating is based on the recent FDA approval of scPharmaceuticals’ supplemental New Drug Application (sNDA) for Furoscix, which now includes treatment for edema in patients with chronic kidney disease (CKD). This approval significantly broadens the drug’s market potential beyond its initial use for heart failure patients, addressing a larger population with a high unmet need for fluid overload treatment. The company plans to make Furoscix available for CKD patients by April 2025, which is expected to enhance adoption rates and capitalize on this expanded label.
Moreover, there is strong interest from nephrologists in using Furoscix as an at-home treatment option for CKD patients, which could lead to increased prescriber awareness and interest. Several factors could further drive the stock’s value, including effective commercial strategies targeting both heart failure and CKD specialists, potential expansion of payer coverage to include CKD, and early signs of strong adoption among nephrologists. Roanna Ruiz remains confident in scPharma’s ability to seize this new opportunity and anticipates more detailed updates from the company’s management.

In another report released on March 7, TD Cowen also maintained a Buy rating on the stock with a $25.00 price target.